Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan · Delayed Price · Currency is TWD 55.60
+2.50 (4.71%)
At close: Oct 8, 2026
Pet Pharm Biotech Revenue
Pet Pharm Biotech had revenue of 127.77M TWD in the half year ending June 30, 2026, with 128.42% growth. This brings the company's revenue in the last twelve months to 265.54M, up 66.98% year-over-year. In the year 2025, Pet Pharm Biotech had annual revenue of 222.03M with 69.88% growth. That makes Pet Pharm Biotech the 38,102nd largest company in the world by revenue and 1,995th in Taiwan.
Revenue (ttm)
265.54M
Revenue Growth
+66.98%
P/S Ratio
12.16
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.23B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.03M | 91.33M | 69.88% |
| Dec 31, 2024 | 130.70M | 12.83M | 10.89% |
| Dec 31, 2023 | 117.87M | 42.13M | 55.62% |
| Dec 31, 2022 | 75.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.